Philogen's primary focus is developing anti-cancer therapeutics barring the normal tissue. Its strategy is to deliver bioactive agents (cytokines or drugs) to the site of disease using antibodies and other ligands that target stromal antigens. This technology has generated a strong proprietary pipeline of clinical-stage products and preclinical compounds for use in an array of disease indications, according to the companies.
Under the agreement, Janssen may exercise the option in the future to use identified ligands as candidates for further drug discovery and development activities.
No financial details of the agreement were disclosed.
Copyright © 2021 scienceboard.net